Acumen doses first patient in Phase 1 trial of ACU193 for early Alzheimer's

Acumen Pharmaceuticals, Inc.

First patient dosed in INTERCEPT-AD Phase 1 trial of ACU193 for early Alzheimer's disease.
ACU193 is the first monoclonal antibody selectively targeting toxic amyloid-beta oligomers (AβOs).
Trial is placebo-controlled, single- and multiple-dose; enrollment ongoing.
CEO Daniel O'Connell: ACU193 has distinct potential to address unmet needs in Alzheimer's.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.